DxTerity Earns SOC 2 Type 2 Compliance, Reinforcing Commitment to Secure Healthcare Data. Read more
  {modal url="index.php?option=com_content&view=category&layout=blog&id=18&Itemid=125" class="modalsign"}{/modal}
DxTerity Earns SOC 2 Type 2 Compliance, Reinforcing Commitment to Secure Healthcare Data Oct 01, 2022
DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus Jun 01, 2022
DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) Gene Signature Testing for Systemic Lupus Erythematosus Patients. May 18, 2022
DxTerity Diagnostics Announces its OSHA Emergency Temporary Standard (ETS) Compliance-Ready COVID-19 Employer Screening Service Nov 05, 2021
COVID-19: Preparing for the Fall Oct 28, 2020
DxTerity Announces a New At-Home COVID-19 Testing Solution Oct 21, 2020
DxTerity Announces Upcoming Launch of COVID-19 Employee Screening Service Mar 26, 2020
DxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization Device Mar 03, 2020
DxTerity Names Brett Swansiger Chief Commercial Officer Feb 03, 2020
DxTerity® Launches Interferon Test for Lupus Nov 08, 2019
DxTerity® Brings Precision Medicine to Systemic Lupus Erythematosus (SLE) Nov 08, 2019
DxTerity Inks Updated Thermo Fisher Licensing Deal Nov 08, 2019
DxTerity Diagnostics IFN-1 Test Oct 29, 2019

Better health management begins
at home

Subscribe to receive the latest information on new developments and products at DxTerity.